Frontiers | Prevalence of the Brazilian TP53 Founder c.1010G>A (p.Arg337His) in Lung Adenocarcinoma: Is Genotyping Warranted in All Brazilian Patients?
TP53 oncomorphic mutations predict resistance to platinum‑ and taxane‑based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma
Time to first treatment and P53 dysfunction in chronic lymphocytic leukaemia: results of the O-CLL1 study in early stage patients | Scientific Reports
Zinc shapes the folding landscape of p53 and establishes a pathway for reactivating structurally diverse cancer mutants | eLife
Concurrent TP53 Mutations Facilitate Resistance Evolution in EGFR-Mutant Lung Adenocarcinoma - Journal of Thoracic Oncology
Clinical implications of subclonal TP53 mutations in acute myeloid leukemia | Haematologica
LRP1B or TP53 mutations are associated with higher tumor mutational burden and worse survival in hepatocellular carcinoma
Mutant p53 elicits context-dependent pro-tumorigenic phenotypes | Oncogene
The cancer-associated, gain-of-function TP53 variant P152Lp53 activates multiple signaling pathways implicated in tumorigenesis - Journal of Biological Chemistry
Targeting Cavity-Creating p53 Cancer Mutations with Small-Molecule Stabilizers: the Y220X Paradigm | ACS Chemical Biology
Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes | Oncogene
High prevalence and allele burden-independent prognostic importance of p53 mutations in an inner-city MDS/AML cohort | Leukemia
Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function | PNAS
Disarming mutant p53 oncogenic function - ScienceDirect
Implications of driver genes associated with a high tumor mutation burden identified using next‑generation sequencing on immunotherapy in hepatocellular carcinoma
IJMS | Free Full-Text | Do Mutations Turn p53 into an Oncogene? | HTML
The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases | Leukemia
Five‐year overall survival rate in patients with oncomorphic and... | Download Scientific Diagram
TP53 alterations of hormone-naïve prostate cancer in the Chinese population | Prostate Cancer and Prostatic Diseases
Cancers | Free Full-Text | TP53 Combined Phenotype Score Is Associated with the Clinical Outcome of TP53-Mutated Myelodysplastic Syndromes | HTML
Targeting the Prion-like Aggregation of Mutant p53 to Combat Cancer | Accounts of Chemical Research
Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others | Nature Reviews Clinical Oncology
Mutations of the p53 Gene as a Prognostic Factor in Aggressive B-Cell Lymphoma | NEJM
TP53 mutations as potential prognostic markers for specific cancers: Analysis of data from The Cancer Genome Atlas and the International Agency for Research on Cancer TP53 Database | bioRxiv
